- Home
- BOLT vs TENX Comparison
BOLT vs TENX Comparison
Compare BOLT & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BOLT
- TENX
- Stock Information
- Founded
- BOLT 2015
- TENX 1967
- Country
- BOLT United States
- TENX United States
- Employees
- BOLT N/A
- TENX N/A
- Industry
- BOLT Biotechnology: Pharmaceutical Preparations
- TENX Biotechnology: Pharmaceutical Preparations
- Sector
- BOLT Health Care
- TENX Health Care
- Exchange
- BOLT Nasdaq
- TENX Nasdaq
- Market Cap
- BOLT 22.6M
- TENX 21.7M
- IPO Year
- BOLT 2021
- TENX N/A
- Fundamental
- Price
- BOLT $0.49
- TENX $6.11
- Analyst Decision
- BOLT Hold
- TENX Strong Buy
- Analyst Count
- BOLT 5
- TENX 4
- Target Price
- BOLT $1.25
- TENX $20.67
- AVG Volume (30 Days)
- BOLT 136.2K
- TENX 28.4K
- Earning Date
- BOLT 03-20-2025
- TENX 03-27-2025
- Dividend Yield
- BOLT N/A
- TENX N/A
- EPS Growth
- BOLT N/A
- TENX N/A
- EPS
- BOLT N/A
- TENX N/A
- Revenue
- BOLT $9,779,000.00
- TENX N/A
- Revenue This Year
- BOLT $9.87
- TENX N/A
- Revenue Next Year
- BOLT N/A
- TENX N/A
- P/E Ratio
- BOLT N/A
- TENX N/A
- Revenue Growth
- BOLT 35.86
- TENX N/A
- 52 Week Low
- BOLT $0.46
- TENX $2.77
- 52 Week High
- BOLT $1.56
- TENX $21.46
- Technical
- Relative Strength Index (RSI)
- BOLT 44.93
- TENX 46.51
- Support Level
- BOLT $0.49
- TENX $5.85
- Resistance Level
- BOLT $0.52
- TENX $6.40
- Average True Range (ATR)
- BOLT 0.03
- TENX 0.30
- MACD
- BOLT -0.00
- TENX -0.09
- Stochastic Oscillator
- BOLT 24.24
- TENX 20.57
About BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on our deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.
About TENX Tenax Therapeutics Inc.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.